MedTrace Logo

Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)

NCT00948857 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2012-09-10

Study results available
· View outcomes & findings →

Summary

The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with open tubes, fertile male partners and evidence of premature ovarian failure.

Conditions

  • Premature Ovarian Failure

Interventions

DIETARY_SUPPLEMENT

Dehydroepiandrosterone

25 mg PO TID

DIETARY_SUPPLEMENT

Placebo

Blinded placebo

Sponsors & Collaborators

  • David H. Barad

    lead OTHER

Principal Investigators

  • David Barad, MD, MS · Center for Human Reproduction

  • Norbert Gleicher, MD · Center for Human Reproduction

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
21 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00948857 on ClinicalTrials.gov